Dec 31, 2025 • AD HOC NEWS
NEUTRAL
The Truth About AbbVie Inc: Is ABBV the Sleeper Stock Gen Z Is Sleeping On?
This article explores whether AbbVie Inc. (ABBV) is a valuable "sleeper stock" overlooked by younger generations favoring trend-driven investments. It delves into ABBV's strong dividend yield, its transition away from reliance on Humira with new growth drugs like Skyrizi and Rinvoq, and its competitive standing against other pharmaceutical giants. The piece concludes that ABBV is a strong contender for long-term investors seeking steady income and healthcare exposure, despite not being a volatile, "viral" stock.
Dec 31, 2025 • Seeking Alpha
NEUTRAL
Pfizer and other drugmakers eying U.S. price hikes (PFE:NYSE)
A new report indicates that Pfizer, GSK, and other major drugmakers are planning to increase the U.S. prices of up to 360 branded medicines next year, with a median increase around 4%. This comes despite previous pressure from administrations to lower drug costs. However, about nine drugs, including Jardiance, are expected to see significant price reductions.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Generate Investment Management Ltd Acquires 6,778 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Generate Investment Management Ltd significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 56.5% during the third quarter, purchasing an additional 6,778 shares, bringing its total holdings to 18,778 shares valued at approximately $10.56 million. Other institutional investors also made substantial moves in REGN stock, with Dodge & Cox increasing its holdings by 64.6% and Norges Bank acquiring a new position worth about $628 million. Analysts maintain a "Moderate Buy" rating for Regeneron, with an average price target of $779.45.
Dec 31, 2025 • openPR.com
SOMEWHAT-BULLISH
Epilepsy Drugs Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG
The global Epilepsy Drugs Market is projected to grow from USD 10.88 billion in 2025 to USD 15.83 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.5%. This growth is driven by rapid innovation, increasing investment, and shifting regional dynamics, necessitating strategic insights for decision-makers. The report provides a deep dive into market structure, segmenting it by type, application, and region, along with detailed profiles of key players to help navigate market opportunities.
Dec 31, 2025 • AD HOC NEWS
NEUTRAL
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast?
GSK plc (ADR) is presented as a stable pharmaceutical giant focusing on vaccines, respiratory treatments, and oncology, offering steady growth and dividends rather than speculative highs. The article suggests that while it lacks the viral hype of meme stocks or AI, its fundamental business strength and global footprint make it a strong candidate for long-term, fundamentals-first investors looking to diversify their portfolios. Investors should consider its defensive nature, income potential, and the inherent risks of the pharma industry such as lawsuits and patent expirations.
Dec 31, 2025 • ts2.tech
NEUTRAL
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY
Bristol-Myers Squibb shares closed slightly higher on Tuesday amidst thin, year-end trading on Wall Street. Investors are looking ahead to the company's early-January dividend record date and its upcoming quarterly earnings report scheduled for February 5, 2026. The stock's performance reflects a modest gain as the broader market saw slight declines, with analysts noting the convergence of growth rates between technology and other sectors in the coming year.